Adderall and Death: It’s Team FDA versus Team Canada!
The Carlat Psychiatry Report, Volume 3, Number 4, April 2005
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
On February 9, 2005, Health Canada (HC) announced that it was suspending sales of Adderall XR in Canada because of concerns that it might lead to sudden death and stroke. The FDA, however, has begged to differ.